GenomedWAR:GEN 78 Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus rates WAR:GEN with a GF Score™ of 78/100 and a GF Value™ of zł37.76 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 95 Medical Diagnostics & Research companies, Genomed ranks better than 70.53% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Genomed's
Operating Income
for the
three
months ended in Mar. 2026 was zł-0.02 Mil. Genomed's Interest Expense for the
three
months ended in Mar. 2026 was zł-0.00 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Genomed's Interest Coverage or its related term are showing as below:
WAR:GEN'
s Interest Coverage Range Over the Past 10 Years
Min: 32.99 Med: 645.5 Max: No Debt
Current: 32.99
WAR:GEN's Interest Coverage is ranked better than 70.53% of 95
companies
in the Medical Diagnostics & Research industry
Industry Median: 9.05
vs WAR:GEN: 32.99
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Genomed Interest Coverage Related Terms
Genomed Interest Coverage Historical Data
* Premium members only.
The historical data trend for Genomed's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
WAR:GEN vs TMO, DHR, IDXX: Interest Coverage Comparison
For the Diagnostics & Research subindustry, Genomed's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomed Interest Coverage vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genomed's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Genomed's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Genomed did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Genomed (WAR:GEN) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Genomed and its competitors. Over the past decade, Genomed's Interest Coverage has ranged from 32.99 to 10,000.00. According to the industry distribution chart, Genomed ranks #28 out of 95 companies in the Medical Diagnostics & Research industry, placing it in the top 29.5%.
Is Genomed's Interest Coverage too high?
Genomed's current Interest Coverage is 0 (At Loss). Over the past 10 years, this metric has ranged from a low of 32.99 to a high of 10,000.00. Based on the distribution chart, Genomed ranks #28 out of 95 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Genomed has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomed's Interest Coverage compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Genomed ranks #28 out of 95 companies for Interest Coverage. This puts Genomed in the upper half of its industry. The industry median Interest Coverage is 9.05. Historically, Genomed's own Interest Coverage has ranged from 32.99 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Diagnostics & Research company?
The median Interest Coverage among Medical Diagnostics & Research companies is 9.05, based on 95 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Genomed and its competitors. For the Medical Diagnostics & Research industry, the median Interest Coverage is 9.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomed's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomed stock overvalued right now?
Based on GuruFocus' analysis, Genomed (WAR:GEN) is currently considered Significantly Undervalued. The stock's GF Value™ is zł37.76, compared to a current price of zł25.80 — trading 31.7% below its estimated fair value. The current Interest Coverage is 0 (At Loss). Genomed's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Genomed (WAR:GEN), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomed (WAR:GEN) Overvalued in 2026?
Based on GuruFocus' analysis, Genomed stock appears to be undervalued.
The current stock price of zł25.80 is trading 31.7% below its estimated GF Value™ of zł37.76.
GuruFocus considers Genomed to be Significantly Undervalued.
Key valuation signals for WAR:GEN:
Interest Coverage: 0 (At Loss)
GF Value™: zł37.76 vs. price of zł25.80 (31.7% below fair value)
No single metric tells the full story. See the WAR:GEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomed SA assembles outstanding molecular biologists and genetic diagnosticians. The company provides diagnostic service that comprises DNA analysis and congenital diseases diagnostics based on DNA sequencing. It offers Diagnostic service and Service for scientific purposes.
78GF Score
Get the complete analysis for WAR:GEN
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:GEN has been successfully added to your 
